No Data
The Three-year Shareholder Returns and Company Earnings Persist Lower as Xiamen Kingdomway Group (SZSE:002626) Stock Falls a Further 4.0% in Past Week
Kim Dawei: 2024 Annual Report Summary
Kim Dawei: 2024 Annual Report
The price increase of Vitamins helped Xiamen Kingdomway Group achieve a 24% increase in net profit last year, while the gross profit margin of the core product coenzyme Q10 continued to be under pressure.|Interpretations
① Xiamen Kingdomway Group had a poor start but ended strong last year, meeting Brokerage expectations; ② The price increase of VA was the main reason for the performance growth, but prices have dropped to low levels this year; ③ Core product coenzyme Q10 has seen strong production and sales but the gross profit continues to decline.
Xiamen Kingdomway Group (002626.SZ): Net income for the year 2024 is 0.342 billion yuan, proposing a payout of 4 yuan.
Gelonghui April 9th丨Xiamen Kingdomway Group (002626.SZ) announced its 2024 annual report, achieving revenue of 3.24 billion yuan in 2024, a year-on-year increase of 4.43%; Net income attributable to shareholders of the listed company was 0.342 billion yuan, a year-on-year increase of 23.59%; Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.339 billion yuan, a year-on-year increase of 20.80%; EPS was 0.56 yuan; A cash dividend of 4 yuan (including tax) will be distributed for every 10 shares to all shareholders.
Xiamen Kingdomway Group (002626.SZ): The health products of its Doctor's Best brand, including deep-sea fish oil softgel products, are currently on sale.
Gelonghui, March 24 – Xiamen Kingdomway Group (002626.SZ) stated on the investor interaction platform that the health supplements under the Doctor's Best brand have deep-sea fish oil soft capsule products available for sale.
